Loading...

BioCardia, Inc.

BCDAW•NASDAQ
Healthcare
Biotechnology
$0.006
$-0.00(-3.17%)

BioCardia, Inc. (BCDAW) Stock Overview

Explore BioCardia, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.9/100

Key Financials

Market Cap10.1K
P/E Ratio-1.33
EPS (TTM)$-3.20
ROE-307.93%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.16

BCDAW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of BioCardia, Inc. (BCDAW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.16.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.33 and a market capitalization of 10.1K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for BCDAWStats details for BCDAW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for BCDAWAnalyst Recommendations details for BCDAW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

CEO

Peter A. Altman

Employees

16

Headquarters

320 Soquel Way, Sunnyvale, DE

Founded

2019

Frequently Asked Questions

;